Achieve Life Sciences, Inc. stock analysis QUIT.US

Achieve Life Sciences, Inc. is a specialty pharmaceutical company focused entirely on the development and eventual commercialization of cytisinicline, a non-nicotine therapeutic aimed at treating nicotine dependence in people who smoke combustible cigarettes or use e-cigarettes. Cytisinicline is a plant-derived alkaloid that functions as a partial agonist to nicotinic acetylcholine receptors in the brain, reducing cravings and withdrawal symptoms when nicotine binds, while dampening the satisfaction nicotine can provide. The company operates in the late-stage clinical phase and is preparing for regulatory review and market entry.

In addition to its central product candidate, cytisinicline, Achieve has completed several clinical studies including ORCA-OL, which examines long-term safety in users of cigarettes and e-cigarettes, and has been granted Breakthrough Therapy designation by the U.S. FDA for vaping cessation. The company has no currently marketed products in the United States, and development, regulatory, manufacturing, and commercialization tasks dominate its operations. Its product pipeline at this time consists of cytisinicline for smoking cessation and for vaping cessation.

Achieve maintains facilities in Bothell, Washington and Vancouver, British Columbia. Its manufacturing supply chain includes third-party manufacturers such as Sopharma AD, which has historically supplied cytisinicline for clinical trials. Regulatory filings indicate a reliance on good manufacturing practices compliance from external producers and engagement with regulatory authorities. The company does not generate revenue from product sales at present and has historically relied on financing via equity, debt, government grants, or similar sources to cover operating losses. Its target markets are primarily the United States, the United Kingdom, and Canada.